Patients | 301 |
Follow up (range) (years) | 3.6 (1.2–5.9) |
One vessel treated | 273 (90.7%) |
Two vessels treated | 28 (9.3%) |
Total number of vessels | 329 |
Failed radiation | 4 (1.3%) |
Second radiation | 4 (1.3%) |
Vessel treated | |
LM | 2 (0.6%) |
LAD | 120 (36.5%) |
RCA | 115 (35.0%) |
LCx | 73 (22.2%) |
SVG | 19 (5.8%) |
Dual antiplatelet treatment | |
None | 51 (16.9%) |
1–3 months | 71 (23.6%) |
6 months | 142 (47.2%) |
>6 months | 37 (12.3%) |
Gp IIb/IIIa inhibitors | 109 (36.2%) |
Study | |
BERT | 30 (10.0%) |
Beta-Cath trial | 13 (4.3%) |
BRIDGE | 11 (3.7%) |
BRIE | 14 (4.7%) |
Compassionate use | 23 (7.6%) |
EURO-START 40 | 12 (4.0%) |
PREVENT | 29 (9.6%) |
Routine use* | 169 (56.1%) |
Source | |
32P | 40 (13.3%) |
90Sr/90Y | 261 (86.7%) |
Source length (vessels) (mm) | |
32P: 27 | 40 (12.2%) |
90Sr/90Y: 30 | 142 (43.2%) |
90Sr/90Y: 40 | 109 (33.1%) |
90Sr/90Y: 60 | 38 (11.6%) |
Tandem radiation† | 48 (14.6%) |
Delayed radiation‡ | 7 (2.1%) |